GLP-1 Agonists and SGLT2 Inhibitors Do Not Increase Autoimmune Risk GLP-1 Agonists and SGLT2 Inhibitors Do Not Increase Autoimmune Risk
Patients with type 2 diabetes prescribed GLP-1 receptor agonists or SGLT2 inhibitors did not have a greater risk of developing autoimmune disease than those prescribed DPP-4 inhibitors.Medscape Medical News
Source: Medscape Nurses Headlines - Category: Nursing Tags: Rheumatology Source Type: news
More News: Autoimmune Disease | Diabetes | Diabetes Type 2 | Endocrinology | Nurses | Nursing | Rheumatology | SGLT2 Inhibitors